仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响

doi:10.3969/j.issn.1001-8131.2025.02.002

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (570 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effects of lenvatinib combined with sintilimab on tumor marker levels and survival in patients with advanced liver cancer.Method A retrospective collection of data was conducted on 96 patients with advanced liver cancer.They were divided into a control group（48 cases）and a study group（48 cases）according to different treatment plans;The control group was treated with lenvatinib,while the study group was treated with lenvatinib combined with sildenafil monoclonal antibody for at least 3 cycles;Compare and analyze the treatment efficacy,tumor marker levels,liver function indicators,quality of life,adverse reactions,and survival status between the two groups.The disease control rate of the research group（70.83%）was higher than that of the control group（41.67%）（P<0.05）;The research group had lower levels of alpha fetoprotein（AFP）,carcinoembryonic antigen（CEA）,abnormal prothrombin（PIVKA II）,carbohydrate antigen（CA199）,total bilirubin（TBIL）,aspartate aminotransferase（AST）,and alanine aminotransferase（ALT）compared to the control group after three cycles of treatment;The study group had higher scores in all dimensions of the EORTC QLQ-C30 quality of life assessment scale for cancer patients treated for three cycles compared to the control group（P<0.05）;There was no statistically significant difference in adverse reactions between the study group（14.58%）and the control group（10.42%）（P>0.05）;The survival rate of the study group was higher than that of the control group,and the median survival time was longer than that of group A（P<0.05）.Conclusion The combination of lenvatinib and xindilimab is effective in the treatment of advanced liver cancer patients,reducing tumor marker levels,alleviating liver function damage,improving quality of life,and increasing survival rate,with good safety.

Key words： Advanced liver cancer Lenvatinib Xindilimumab Tumor markers Survival situation

Received: 20 February 2025

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhou Guohui

Cite this article:

Zhou Guohui. The Effect of Lenvatinib Combined with Xindilimab on Tumor Marker Levels and Survival in Patients with Advanced Liver Cancer[J]. journal1, 2025, 45(2): 4-4.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2025.02.002 OR http://www.hrbyybjb.org.cn/EN/Y2025/V45/I2/4

[1] Wang W,Lu K,Jiang X,et al.Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer[J].J Exp Clin Cancer Res,2023,42(1):142.
[2] Yang X,Wang J,Wang H.Association between sleep traits and primary liver cancer:A Mendelian randomization analysis[J].Eur J Clin Invest,2023,53(8):e14002.
[3] Wang J,Yu H,Dong W,et al.N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/beta-Catenin and Hippo Signaling Pathways[J].Gastroenterology,2023,164(6):990-1005.
[4] 徐彬,李小龙,朱小东,等.在接受仑伐替尼联合PD-1抗体治疗的不可切除肝细胞癌患者肝切除术前行门静脉栓塞术的研究[J].中华肝胆外科杂志,2022,28(1):21-27.
[5] 黎旺红,唐津天,易超,等.信迪利单抗,仑伐替尼联合TACE成功转化巨大肝细胞癌一例[J].肝胆胰外科杂志,2024,36(5):294-296,301.
[6] 卢芳,施尧,张晨曦,等.信迪利单抗治疗晚期肝癌的有效性及安全性分析[J].医学研究生学报,2023,36(8):852-855.
[7] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1137-1164.
[8] Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid Tumours-Revised RECIST Guideline (Version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[9] 王岩,朱琳,陈鹏.肿瘤患者生命质量测定量表EORT CQLQ-C30维文版评价[J].中国卫生统计,2015,32(3):512-513.
[10] Huang DQ,Singal AG,Kono Y,et al.Changing global epidemiology of liver cancer from 2010 to 2019:NASH is the fastest growing cause of liver cancer[J].Cell Metab,2022,34(7):969-977.
[11] Huang M,Long J,Yao Z,et al.METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma[J].Cancer Res,2023,83(1):89-102.
[12] Pan J,Zhang M,Dong L,et al.Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma[J].Autophagy,2023,19(4):1184-1198.
[13] 费睿成,亓民.PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果[J].实用中西医结合临床,2024,24(10):16-19.
[14] 陈秋平,邵明义,张容容,等.信迪利单抗联合化疗方案一线治疗晚期,复发或转移性食管鳞状细胞癌的成本-效用分析[J].中国药房,2023,34(3):345-349.
[15] 叶小荣,程涛,易弼顺.信迪利单抗联合XELIRI方案治疗结直肠癌的疗效及预后影响因素[J].中国药物与临床,2024,24(16):1068-1072.
[16] 王勇军,王志英,王红英,等.信迪利单抗联合仑伐替尼治疗中晚期肝癌临床观察[J].肿瘤基础与临床,2024,37(5):514-517.